358 related articles for article (PubMed ID: 14642400)
21. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Shepherd J; Betteridge J; Van Gaal L;
Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
[TBL] [Abstract][Full Text] [Related]
22. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
23. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.
Dayspring T; Pokrywka G
Curr Atheroscler Rep; 2006 Sep; 8(5):356-64. PubMed ID: 16901405
[TBL] [Abstract][Full Text] [Related]
24. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
Després JP; Lemieux I; Robins SJ
Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
[TBL] [Abstract][Full Text] [Related]
25. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
26. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
27. Atherogenic dyslipidemia in the cardiometabolic syndrome.
Govindarajan G; Chowdhury N; Flaker G
J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
[No Abstract] [Full Text] [Related]
28. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
Gonna H; Ray KK
Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():6-16. PubMed ID: 31002453
[TBL] [Abstract][Full Text] [Related]
29. Catabolism of lipoproteins and metabolic syndrome.
Therond P
Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
[TBL] [Abstract][Full Text] [Related]
31. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
Chapman MJ; Guérin M; Bruckert E
Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
[TBL] [Abstract][Full Text] [Related]
32. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.
Grundy SM
Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809
[TBL] [Abstract][Full Text] [Related]
33. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Després JP
Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
[TBL] [Abstract][Full Text] [Related]
34. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
35. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
36. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
37. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
38. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
39. Effects of fibrates on serum metabolic parameters.
Elisaf M
Curr Med Res Opin; 2002; 18(5):269-76. PubMed ID: 12240789
[TBL] [Abstract][Full Text] [Related]
40. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
